UTHR Q1 2023 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$507M+9.7% YoY

Gross Profit

$455M89.7% margin

Operating Income

$284M56.1% margin

Net Income

$241M47.5% margin

EPS (Diluted)

$4.86

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$375M

Free Cash Flow

$334M

Stock-Based Comp.

-$12M

Balance Sheet

Total Assets

$6.3B

Total Liabilities

$1.2B

Stockholders' Equity

$5.1B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$507M	$462M	+9.7%
Gross Profit	$455M	$436M	+4.3%
Operating Income	$284M	$288M	-1.3%
Net Income	$241M	$240M	+0.4%

Revenue Segments

Tyvaso

$238M47%

Remodulin

$121M24%

Orenitram

$88M17%

Unituxin

$49M10%

Adcirca

$7M1%

Product and Service, Other

$3M0%

Geographic Segments

UNITED STATES

$470M93%

Non-US

$37M7%